Kyowa Kirin pharma growth lacklustre despite strong Nesp sales
This article was originally published in Scrip
Executive Summary
Despite good growth for mainstay product Nesp (darbepoetin alfa; licensed from Amgen), net pharmaceutical sales at Kyowa Hakko Kirin rose by just 1% to ¥210.4 billion ($2.56 billion) in calendar 2010, held back mainly by last April's general reimbursement price cut in Japan.